157 related articles for article (PubMed ID: 37141845)
1. Impact of prostate imaging quality (PI-QUAL) score on the detection of clinically significant prostate cancer at biopsy.
Brembilla G; Lavalle S; Parry T; Cosenza M; Russo T; Mazzone E; Pellegrino F; Stabile A; Gandaglia G; Briganti A; Montorsi F; Esposito A; De Cobelli F
Eur J Radiol; 2023 Jul; 164():110849. PubMed ID: 37141845
[TBL] [Abstract][Full Text] [Related]
2. Impact of PI-QUAL on PI-RADS and cancer yield in an MRI-TRUS fusion biopsy population.
Pötsch N; Rainer E; Clauser P; Vatteroni G; Hübner N; Korn S; Shariat SF; Helbich TH; Baltzer PAT
Eur J Radiol; 2022 Sep; 154():110431. PubMed ID: 35803101
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for prostate cancer in men with false-negative mpMRI: A retrospective single center cohort study of image quality scores and clinical parameters.
Pausch AM; Ghafoor S; Kluckert J; Rupp NJ; Eberli D; Hötker AM
Eur J Radiol; 2024 Jan; 170():111227. PubMed ID: 38039782
[TBL] [Abstract][Full Text] [Related]
4. Structured approach to resolving discordance between PI-RADS v2.1 score and targeted prostate biopsy results: an opportunity for quality improvement.
Arcot R; Sekar S; Kotamarti S; Krischak M; Michael ZD; Foo WC; Huang J; Polascik TJ; Gupta RT
Abdom Radiol (NY); 2022 Aug; 47(8):2917-2927. PubMed ID: 35674785
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
Lim CS; Abreu-Gomez J; Carrion I; Schieda N
AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
[No Abstract] [Full Text] [Related]
6. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
[TBL] [Abstract][Full Text] [Related]
7. Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy.
Thaiss WM; Moser S; Hepp T; Kruck S; Rausch S; Scharpf M; Nikolaou K; Stenzl A; Bedke J; Kaufmann S
World J Urol; 2022 Oct; 40(10):2431-2438. PubMed ID: 35922717
[TBL] [Abstract][Full Text] [Related]
8. Variability of mpMRI diagnostic performance according to the upfront individual patient risk of having clinically significant prostate cancer.
Pellegrino F; Stabile A; Sorce G; Mazzone E; Cannoletta D; Cirulli GO; Quarta L; Leni R; Robesti D; Brembilla G; Gandaglia G; De Cobelli F; Montorsi F; Briganti A
Prostate; 2024 Apr; 84(5):473-478. PubMed ID: 38149793
[TBL] [Abstract][Full Text] [Related]
9. Multi-reader evaluation of different image quality scoring systems in prostate MRI.
Hötker AM; Njoh S; Hofer LJ; Held U; Rupp NJ; Ghafoor S; Stocker D; Eberli D; Donati OF
Eur J Radiol; 2023 Apr; 161():110733. PubMed ID: 36780738
[TBL] [Abstract][Full Text] [Related]
10. Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis.
Mazzone E; Stabile A; Pellegrino F; Basile G; Cignoli D; Cirulli GO; Sorce G; Barletta F; Scuderi S; Bravi CA; Cucchiara V; Fossati N; Gandaglia G; Montorsi F; Briganti A
Eur Urol Oncol; 2021 Oct; 4(5):697-713. PubMed ID: 33358543
[TBL] [Abstract][Full Text] [Related]
11. Prostate Imaging Quality (PI-QUAL): A New Quality Control Scoring System for Multiparametric Magnetic Resonance Imaging of the Prostate from the PRECISION trial.
Giganti F; Allen C; Emberton M; Moore CM; Kasivisvanathan V;
Eur Urol Oncol; 2020 Oct; 3(5):615-619. PubMed ID: 32646850
[TBL] [Abstract][Full Text] [Related]
12. Impact of prostate MRI central review over the diagnostic performance of MRI-targeted biopsy: should we routinely ask for an expert second opinion?
Stabile A; Sorce G; Barletta F; Brembilla G; Mazzone E; Pellegrino F; Cannoletta D; Cirulli GO; Gandaglia G; De Cobelli F; Montorsi F; Briganti A
World J Urol; 2023 Nov; 41(11):3231-3237. PubMed ID: 36943477
[TBL] [Abstract][Full Text] [Related]
13. Prostate MRI quality: clinical impact of the PI-QUAL score in prostate cancer diagnostic work-up.
Karanasios E; Caglic I; Zawaideh JP; Barrett T
Br J Radiol; 2022 May; 95(1133):20211372. PubMed ID: 35179971
[TBL] [Abstract][Full Text] [Related]
14. The diagnostic accuracy of multiparametric magnetic resonance imaging before biopsy in the detection of prostate cancer.
Otti VC; Miller C; Powell RJ; Thomas RM; McGrath JS
BJU Int; 2019 Jan; 123(1):82-90. PubMed ID: 29804315
[TBL] [Abstract][Full Text] [Related]
15. MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: follow-up of a PRECISION trial-like retrospective cohort.
Luzzago S; de Cobelli O; Mistretta FA; Piccinelli ML; Lorusso V; Morelli M; Bianchi R; Catellani M; Cozzi G; Di Trapani E; Pricolo P; Alessi S; Ferro M; Marvaso G; Matei DV; Jereczek-Fossa BA; Petralia G; Musi G
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):406-413. PubMed ID: 32989259
[TBL] [Abstract][Full Text] [Related]
16. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.
Emmett L; Buteau J; Papa N; Moon D; Thompson J; Roberts MJ; Rasiah K; Pattison DA; Yaxley J; Thomas P; Hutton AC; Agrawal S; Amin A; Blazevski A; Chalasani V; Ho B; Nguyen A; Liu V; Lee J; Sheehan-Dare G; Kooner R; Coughlin G; Chan L; Cusick T; Namdarian B; Kapoor J; Alghazo O; Woo HH; Lawrentschuk N; Murphy D; Hofman MS; Stricker P
Eur Urol; 2021 Dec; 80(6):682-689. PubMed ID: 34465492
[TBL] [Abstract][Full Text] [Related]
17. Which men with non-malignant pathology at magnetic resonance imaging-targeted prostate biopsy and persistent PI-RADS 3-5 lesions should repeat biopsy?
Castellani D; Pace G; Cecchini S; Franzese C; Cicconofri A; Romagnoli D; Del Rosso A; Possanzini M; Paci E; Dellabella M; Pierangeli T
Urol Oncol; 2022 Oct; 40(10):452.e9-452.e16. PubMed ID: 35871992
[TBL] [Abstract][Full Text] [Related]
18. Inter-reader agreement of the PI-QUAL score for prostate MRI quality in the NeuroSAFE PROOF trial.
Giganti F; Dinneen E; Kasivisvanathan V; Haider A; Freeman A; Kirkham A; Punwani S; Emberton M; Shaw G; Moore CM; Allen C
Eur Radiol; 2022 Feb; 32(2):879-889. PubMed ID: 34327583
[TBL] [Abstract][Full Text] [Related]
19. A clinical available decision support scheme for optimizing prostate biopsy based on mpMRI.
Hou Y; Jiang KW; Zhang J; Bao ML; Shi HB; Qu JR; Cheng G; Zhang YD
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):727-734. PubMed ID: 35067674
[TBL] [Abstract][Full Text] [Related]
20. Systematic versus Targeted Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy among Men with Visible Lesions.
Patel HD; Koehne EL; Shea SM; Fang AM; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
J Urol; 2022 Jan; 207(1):108-117. PubMed ID: 34428091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
